Curis to Present Updated Data From the TakeAim Leukemia Study
LEXINGTON, Mass., May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibi
Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript
Curis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Curis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $26 Price Target
HC Wainwright & Co. analyst Edward White reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $26 price target.
Curis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 53.54% HC Wainwright & Co. → $26 Reiterates Buy → Buy 02/09/2024 53.54% HC Wainwright & Co. $51
Curis Buy Rating Affirmed on Strong Earnings and Promising Emavusertib Trials
Curis Inc. Insiders Hold Steady: No New Trades Signal Confidence or Complacency?
Curis, Inc. (CRIS) Q1 2024 Earnings Call Transcript
Curis, Inc. (CRIS) Q1 2024 Earnings Call Transcript
Curis | 10-Q: Quarterly report
Curis (CRIS.US): The 2024 Q1 financial report achieved revenue of US$2,086 million, with a previous value of US$2.297 million and an expected value of US$2.4 million; earnings per share were -2.05 US dollars, previous value was -2.40 US dollars, and expec
Curis (CRIS.US): The 2024 Q1 financial report achieved revenue of US$2,086 million, with a previous value of US$2.297 million and an expected value of US$2.4 million; earnings per share were -2.05 US dollars, previous value was -2.40 US dollars, and expected value was -2.12 US dollars.
Earnings Flash (CRIS) CURIS Reports Q1 Revenue $2.1M, Vs. Street Est of $2M
08:10 AM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (CRIS) CURIS Reports Q1 Revenue $2.1M, vs. Street Est of $2M
Curis: Runway to Fund Planned Operations Into 2025 >CRIS
Curis: Runway to Fund Planned Operations Into 2025 >CRIS
Curis Inc Q1 Loss Beats Estimates
Curis 1Q Loss $11.9M >CRIS
Curis 1Q Loss $11.9M >CRIS
Curis Q1 24 Earnings Conference Call At 8:30 AM ET
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
LEXINGTON, Mass., April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis, Inc. (NASDAQ:CRIS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Curis, Inc. (NASDAQ:CRIS) shares have continued their recent momentum with a 36% gain in the last month alone. The bad news is that even after the stocks recovery in the last 30 days, shareholders
Changes in Hong Kong stocks | China Tongshi (01763) rose more than 4%, China Nuclear Qualcomm officially has the capacity to produce and supply Nuclides such as Wancuri GMP grade N-177
The Zhitong Finance App learned that China's Tongbo (01763) rose by more than 4%. As of press release, it had risen 3.85% to HK$10.26, with a turnover of HK$1,228,800. According to the news, the China Communications Agency announced that recently, the first domestic production line with an annual output of Wanjuli grade Carrier-free Zi-177 GMP and an annual production capacity of 1,000 germanium 68Ge-68Ga generators was fully completed and put into operation, marking the actual realization of large-scale commercialization of the two GMP-grade GMP-grade GE-177 and Gallium-68 medical nuclides. The smooth commissioning of the production line will effectively mitigate domestic supply shortages of Zn-177 and Gallium-68
Top 3 Health Care Stocks That May Collapse In Q2
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indica
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass., April 5, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced t
No Data